EAPB: New President, New Board – To New Borders

In October last year EAPB had the first elections in its history after foundation in the year 2000. Elected was a new Executive Committee consisting of President, First  and Second Vice President, First Scientific Secretary, Second Scientific Secretary & Treasurer. In addition, the six appointed Governors representing the corporate members were elected by the companies.
, den 16. April 2004

Executive Committee (five Governors) and appointed Corporate Governors (six) form the deciding Board of EAPB. An important decision was made to change the Standing Order of EAPB to improve the EAPB infrastructure considering the tremendous growth of the society (approximately 1400 members and 50 corporate members (companies) in four years). The position of a General Secretary was introduced. The General Secretary is appointed member of the Executive Committee, that means the EC totals up to six Governors. Details see on the right. Special invited representatives of the EAPB Board Meetings: Gerd Kielburger, Vogel Media Group, Editor-in-Chief of NewDrugs; Assoc. Prof. Dr. Conrad Coester, University of Munich, Head of Scientific Advisory Board/Scientific Editor of NewDrugs.

Report by outgoing President Prof. R. H. Müller

The foundation meeting of the new Board was held in Berlin on Monday, 1st December 2003. Prof. Müller as first President of EAPB handed over to the new President Dr. Sven Stegemann, former First Vice President. At this occasion Prof. Müller summarised the achievements of the society and the first EAPB Board. The idea to found EAPB was born in a hotel room in Boston/Massachusetts in 1999 by Dr. G. Hildebrand/Schering AG, Dr. Oliver Kayser/Free University of Berlin and Prof. Rainer H. Müller/Free University and PharmaSol GmbH Berlin. Important milestones and achievements in EAPB history are:

•  foundation of EAPB in Berlin on 2nd April 2000
• alliance with MEGRA/PEFRAS in the area of regulatory affairs
• alliance with the European Federation of Biotechnology (EFB) in the area of biotechnology
• establishment of industrial journal NewDrugs in cooperation with Vogel Media Group
• building up of membership: approximately 1300 personal members and 50 corporate members until December 2003
• solid financial “black” figures
• cooperation agreement with AAPS
• participation in biannual congresses of APV and APGI
• begin of regular participation in the European Congress on Biotechnology organised by EFB
• foundation of local representations Poland & Eastern Europe (Polish Pharmaceutical Society) and Italy (AFI – Associazione Pharmaceutici Industria)
• The outgoing President expressed his sincere thanks to all EAPB members who contributed to this outstanding success in founding and establishing this new society